Regeneron price target raised to $360 from $336 at Piper Jaffray

Piper Jaffray believes Regeneron's Phase III data on EYLEA in Diabetic Macular Edema that was presented over the weekend supports label expansion with blockbuster potential. Piper raised its price target for shares to $360 and reiterates an Overweight rating on the stock.

View Comments (0)